Fibromyalgia Treatment Market size is slated to experience commendable growth by 2027. Developments in the market can be linked with factors such as increasing occurrence of rheumatic diseases and unmet medical needs in fibromyalgia treatment. Expansion of the global geriatric population is a major reason behind the high occurrence rate of fibromyalgia since the disease is associated with age. Growing public awareness about the condition and ongoing research and development in pain management will augment the market expansion.
Fibromyalgia is one of the most common types of chronic pain which affects nearly 3-6% of the global population, according to the U.S. National Fibromyalgia Association. It is a type of musculoskeletal disorder characterized by prominent pain accompanied by fatigue, sleep, mood swings, and loss of memory. Common ways to treat fibromyalgia include therapy, medications, aerobic exercise, and stress reduction, among others. Antidepressants, anticonvulsants, analgesics, and muscle relaxants are commonly prescribed to treat depression, anxiety, pain, and fatigue associated with the disease.
Antidepressant segment of the market is expected to witness notable share over 2021-2027 on account of the increasing occurrence of anxiety and depression in fibromyalgia patients. These drugs can also help patients in alleviating pain and fatigue. Physicians commonly prescribe muscle relaxants along with antidepressants to achieve faster and more effective results. The growing occurrence of fibromyalgia, especially among older adults, will positively influence antidepressant demand.
Market share from hospitals is likely to grow substantially in the forthcoming years. A large number of individuals with fibromyalgia, particularly those with more severe symptoms, need regular hospital visitations for proper check-up and follow-up treatment. Availability of specialized healthcare experts, advanced infrastructure, and latest equipment and technologies in hospital settings make them preferable among consumers.
North America fibromyalgia treatment market will record appreciable gains by the year 2027 considering the widespread occurrence of the problem. The condition affects an estimated 10 million people in the U.S. alone, as per the National Fibromyalgia Association. High rate of fibromyalgia diagnosis, availability of advanced approved products to manage the disorder, and a well-established healthcare system makes the region a profitable market.
AbbVie, Allergan (AbbVie), Abbott, AstraZeneca, Astellas Pharma, Bayer AG, Cephalon, Inc. (Teva Pharmaceuticals), Boehringer Ingelheim, F. Hoffmann-La Roche, Eli Lilly, Johnson & Johnson Services, GlaxoSmithKline, Pfizer, Novartis, and Sanofi are currently some of the biggest names in the market. Market players are placing their focus on efforts on developing novel solutions for treatment of fibromyalgia and associated conditions. In June 2021, Virios Therapeutics, Inc. had announced results from its phase-2a clinical trial PRID-201 which showed that IMC-1 was better tolerated in fibromyalgia patients.
Many companies are also relying on strategies such as mergers, acquisitions, and collaborations to gain a competitive edge. In May 2020, for instance, AbbVie had acquired Allergan plc to expand its brand portfolio and strengthen its position in the worldwide biopharmaceutical sector.
Management of fibromyalgia, which has unique needs and concerns, has been challenging for patients during the COVID-19 pandemic situation. A number of studies have shown that those with fibromyalgia could experience aggravated pain-related symptoms due to increased anxiety during the pandemic. These factors could lead to an increase in the demand for fibromyalgia drugs such as antidepressants, anticonvulsants, analgesics, and muscle relaxers.
The pandemic has also caused a rapid rise in telehealth adoption. Telemedicine services have gained wide popularity among fibromyalgia patients as the disease often makes it harder for patients to attend the doctor’s appointment owing to pain and fatigue. A large number of patients are relying on telehealth platforms for treatment, follow-up, and medication refills. The aforementioned trends are likely to persist for quite some time in the future but are unlikely to affect the market forecast too much.
Market, by treatment, 2013-2024 (USD Million)
Market, by drug class, 2013-2024 (USD Million)
Market, by end-user, 2013-2024 (USD Million)
The above information is provided for the following regions and countries: